Key clinical point: Bioimpedance spectroscopy may better identify lymphedema progression in women at risk for breast cancer–related lymphedema over the traditionally used method of monitoring arm circumference with a tape measure.
Major finding: In the bioimpedance spectroscopy group, there was a 10% absolute reduction and 67% relative reduction in lymphedema progression.
Study details: Interim analysis from the PREVENT trial.
Disclosures: The study was funded by ImpediMed. Dr. Ridner reports being the principal investigator for ImpediMed and Tactile Medical through work agreements contracted between the companies and her institution.
REPORTING FROM ASBS 2019